Postoperative radiation therapy for patients who have resected non-small cell lung cancer

Henry Wagner

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

The role of adjuvant postoperative therapy for patients who have resected non-small cell lung cancer (NSCLC) has been controversial. Recent large trials and meta-analysis support a modest, but significant, survival benefit for postoperative adjuvant chemotherapy. Postoperative radiation therapy has little potential benefit in patients who have N0 or N1 disease and should not be used routinely in these patients. There are suggestions of benefit for patients who have N2 disease, but adequately powered trials have not been conducted to demonstrate a possible small, but clinically worthwhile, survival benefit in this subgroup. Central nervous system relapse has emerged as an increasing problem for patients who have NSCLC; trials of prophylactic cranial irradiation are underway in several cooperative trial groups.

Original languageEnglish (US)
Pages (from-to)283-302
Number of pages20
JournalHematology/Oncology Clinics of North America
Volume19
Issue number2
DOIs
StatePublished - Apr 2005

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Postoperative radiation therapy for patients who have resected non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this